Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise for Hard-to-Treat lung cancer

NCT ID NCT05801029

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will receive the drug combination as their first treatment. The main goals are to check side effects and see how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

  • Research Site

    Hong Kong, 150001, Hong Kong

  • Research Site

    Hong Kong, 999077, Hong Kong

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Shatin, 00000, Hong Kong

  • Research Site

    George Town, 10990, Malaysia

  • Research Site

    Kota Bharu, 15586, Malaysia

  • Research Site

    Kuala Lumpur, 50586, Malaysia

  • Research Site

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    Kuantan, 25100, Malaysia

  • Research Site

    Kuching, 93200, Malaysia

  • Research Site

    Singapore, 169610, Singapore

  • Research Site

    Singapore, 308433, Singapore

  • Research Site

    Anyang-si, 14068, South Korea

  • Research Site

    Busan, 49241, South Korea

  • Research Site

    Daegu, 42415, South Korea

  • Research Site

    Seoul, 08308, South Korea

  • Research Site

    Seoul, 5030, South Korea

  • Research Site

    Kaohsiung City, 82445, Taiwan

  • Research Site

    Taichung, 404, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 73657, Taiwan

  • Research Site

    Taipei, 10048, Taiwan

  • Research Site

    Taipei, 110, Taiwan

  • Research Site

    Yunlin, 640, Taiwan

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10400, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Chiang Mai, 50200, Thailand

  • Research Site

    Songkhla, 90110, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.